BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23782380)

  • 1. Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Watanabe A; Chansu S; Ogawa A; Asami K; Imamura M
    Pediatr Int; 2013 Jun; 55(3):e56-8. PubMed ID: 23782380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
    Czyz A; Lewandowski K; Kroll R; Komarnicki M
    Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
    Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Caocci G; Vacca A; Ledda A; Murgia F; Piras E; Greco M; Arras M; Atzeni S; Littera R; La Nasa G
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):652-4. PubMed ID: 22240733
    [No Abstract]   [Full Text] [Related]  

  • 7. Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation.
    Ishida Y; Terasako K; Oshima K; Sakamoto K; Ashizawa M; Sato M; Kikuchi M; Kimura S; Nakasone H; Okuda S; Kako S; Yamazaki R; Nishida J; Kanda Y
    Int J Hematol; 2010 Oct; 92(3):542-6. PubMed ID: 20824399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.
    Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
    Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Teng CL; Yu JT; Chen HC; Hwang WL
    Ann Hematol; 2013 Aug; 92(8):1137-9. PubMed ID: 23307602
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Gruber F; Mustjoki S; Porkka K
    Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib after allogeneic stem cell transplantation in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    de Castro CG; Gregianin LJ; Meneses CF; Brunetto AL
    Pediatr Blood Cancer; 2009 Dec; 53(6):1161. PubMed ID: 19621456
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
    IMAHASHI N; TOKUNAGA M; NISHIWAKI S; YANAGISAWA M; OZAWA Y; MIYAMURA K
    Rinsho Ketsueki; 2009 Nov; 50(11):1612-5. PubMed ID: 20009435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
    Sonmez M; Cobanoglu U; Ovali E; Omay SB
    J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
    [No Abstract]   [Full Text] [Related]  

  • 16. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study.
    Guan F; Yang L; Chen Y; Shi J; Song X; Lai X; Lu Y; Liu L; Ouyang G; Zhao Y; Yu J; Xu Y; Lan J; Fu H; Zhao Y; Qiu X; Zhu P; Cai Z; Huang H; Luo Y
    Cancer; 2024 Jun; 130(12):2139-2149. PubMed ID: 38315517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
    Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
    Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
    Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approved dasatinib regimen available for clinical use.
    Snyder DS
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):285-92. PubMed ID: 19275507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.